Genome&Company

지놈앤컴퍼니 · 314130

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$179.8M (₩248.1B)

Overview

Genome&Company is a drug-discovery company that develops experimental cancer treatments, including antibody-drug conjugates (ADCs, which attach a toxic payload to an antibody to target tumour cells) and immune-oncology therapies that help the immune system attack cancer.

It operates on KOSDAQ, South Korea's tech and small-cap exchange. Its core business model is to discover and develop drug candidates using its proprietary GNOCLE™ platform, then license the resulting technology to other pharmaceutical companies rather than advancing drugs to market itself.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$17.8M

▼ −11.4% YoY

Operating profit · FY2025

−US$21.2M

Loss widened

Net income · FY2025

−US$5.6M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$10.4M(₩14.3B)	US$20.1M(₩27.7B)	US$17.8M(₩24.6B)
Operating profit	−US$39.9M(−₩55.1B)	−US$17.5M(−₩24.2B)	−US$21.2M(−₩29.2B)
Net income	−US$36.7M(−₩50.7B)	−US$19.5M(−₩26.8B)	−US$5.6M(−₩7.7B)

Revenue

FY2023US$10.4M
FY2024US$20.1M
FY2025US$17.8M

Operating profit

FY2023−US$39.9M
FY2024−US$17.5M
FY2025−US$21.2M

Net income

FY2023−US$36.7M
FY2024−US$19.5M
FY2025−US$5.6M

Key ratios (FY2025)

ROE

-6.7%

Debt/Eq

26.6%

Op. margin

-118.9%

Net margin

-31.3%

Rev. YoY

▼ −11.4%

Why it matters

The company has completed technology-transfer deals with Ellipses Pharma Limited and Debiopharm, licensing out two separate novel-target programmes to those named global partners.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?